Kerendia (finerenone) / Bayer - LARVOL DELTA

Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future. (PubMed, Diabetes Ther) - "Key therapeutic agents-including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual GLP-1/glucose-dependent insulinotropic polypeptide RAs, sodium glucose co-transporter inhibitors and the nonsteroidal mineralocorticoid receptor antagonist (MRA) finerenone-offer multi-organ benefits...This review advocates for an integrated CKM framework, exploring treatment strategies, emerging therapies and technological innovations. It also examines the role of artificial intelligence and digital health tools in risk stratification, early diagnosis and long-term condition management, alongside ethical and regulatory considerations."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Genetic Disorders • Heart Failure • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Nephrology • Obesity • Renal Disease • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Analysis of the prespecified FIDELITY pooled patient dataset examined the efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate. (PubMed, Kidney Int) - "The cardiovascular and kidney benefits of finerenone were not modified by an acute eGFR change after drug initiation."

Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Is the Efficacy of Finerenone Related to Obesity Type or Explained by the Obesity Paradox in HFmrEF/HFpEF? (PubMed, J Am Coll Cardiol) - No abstract available

Journal • Cardiovascular • Genetic Disorders • Obesity

What a MES!: A Case of Abiraterone-induced Mineralocorticoid Excess Syndrome (ENDO 2025) - "However, its dual inhibition of 17α-hydroxylase and 17,20-lyase can lead to adverse effects from cortisol suppression.A 79-year-old male with prostate carcinoma and bone metastases on Triptorelin pamoate every six months and abiraterone 250 mg twice daily with prednisone 5 mg once daily for over a year has hypertension with more than three anti-hypertensive medications, including a diuretic, and also has diabetes with chronic kidney disease...Abiraterone was discontinued, and prednisone was switched to dexamethasone due to its lack of mineralocorticoid activity. As amiloride was unavailable, finerenone, a selective mineralocorticoid receptor antagonist, was initiated.Abiraterone inhibits CYP17A1, reducing cortisol production by blocking 17α-hydroxylase and suppressing androgen synthesis, key for prostate cancer progression...Finerenone, a novel, selective MRA, is as effective as spironolactone with fewer side effects and better cardiovascular outcomes, particularly in..."

Clinical • Cardiovascular • Castration-Sensitive Prostate Cancer • Chronic Kidney Disease • Diabetes • Endocrine Disorders • Genito-urinary Cancer • Hypertension • Metabolic Disorders • Nephrology • Oncology • Prostate Cancer • Renal Disease • Solid Tumor • AR

Adrenal artery embolization for bilateral primary aldosteronism (ENDO 2025) - "Both the captopril and saline tests failed to suppress aldosterone...His medication regimen included spironolactone 20 mg BID, finerenone 20 mg QD, nifedipine 30 mg BID, irbesartan 150 mg QD, and KCl 1 g BID, maintaining HBPM below 140/80 mmHg. For refractory bilateral primary aldosteronism, bilateral adrenal artery embolization lowers aldosterone levels and reduces antihypertensive medications as a palliative therapy without causing corticosteroid insufficiency.*. .*"

Cardiovascular • Endocrine Disorders • Erectile Dysfunction • Hypertension • Palliative care • Renal Disease • CXCR4

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism: A Pilot Randomized Controlled Trial (ENDO 2025) - "Abstract is embargoed at this time."

Clinical • Endocrine Disorders

Adrenal Dysfunction and Cardiometabolic Comorbidities Associated with Weight Cycling in Postmenopausal Conditions (ENDO 2025) - "These mice developed heart failure with preserved ejection fraction, which was prevented by the use of the mineralocorticoid receptor antagonist, finerenone. Surprisingly, OVX mice on Yoyo diet displayed an increase in adrenal gland weight, accompanied by significant morphological and functional remodeling of the adrenal cortex.The absence of estrogen leads to cardiometabolic disorders that are worsened by the Yoyo diet, as well as adrenal dysfunction, which could, in turn, contribute to the worsening of cardiometabolic comorbidities.*. .*"

Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Genetic Disorders • Heart Failure • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus • LEP

Finerenone Exerts Anti-Fibrotic Effects in the Liver of Mice with Hepatic Fibrosis Through TGF-β1 Expression and Activation (ENDO 2025) - "The overall findings of this study emphasize finerenone's robust effects in mitigating liver fibrosis in MCD-fed db/db mice, highlighting its potential as a novel therapeutic agent in MASH.*. .*"

Preclinical • Cardiovascular • Fibrosis • Genetic Disorders • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • MMP13 • TGFB1

Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme. (PubMed, Eur Heart J) - "This integer risk score for new-onset hyperkalaemia in patients with chronic kidney disease and Type 2 diabetes could facilitate tailored treatment strategies and mitigate hyperkalaemia in high-risk patients."

Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

The interplay between heart failure and chronic kidney disease. (PubMed, Diabetes Obes Metab) - "It is also essential to understand the role of renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide-1 receptor agonists in managing these conditions. Lifestyle modifications should also be recommended. This review discusses factors contributing to the interplay between HF and CKD and the key role of healthcare professionals in providing appropriate treatment for the co-existing diseases."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Nephrology • Obesity • Renal Disease

Optimize@Home: Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (clinicaltrials.gov) - P4 | N=10 | Enrolling by invitation | Sponsor: University Medical Center Groningen | Trial completion date: Nov 2024 ➔ Oct 2025 | Trial primary completion date: Oct 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial. (PubMed, Eur J Heart Fail) - P3 | "In patients with HFmrEF/HFpEF, the beneficial effects of finerenone on clinical events and symptoms were consistent, regardless of COPD status."

Journal • Asthma • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Chronic Obstructive Pulmonary Disease • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hypertension • Immunology • Obesity • Peripheral Arterial Disease • Pulmonary Disease • Respiratory Diseases

Effectiveness and safety of finerenone in the treatment of IgA Nephrology patients: a retrospective, real-world study. (PubMed, Int Urol Nephrol) - "This real-world study demonstrated the efficacy and safety of finerenone treatment in IgAN patients during a 3-6 months follow-up period, providing clinical evidence to support its use in IgAN. However, further prospective research is needed to prove these findings."

Journal • Real-world evidence • Retrospective data • Diabetic Nephropathy • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones. (PubMed, Eur Heart J Suppl) - "Lately, the class of mineralocorticoid receptor antagonist drugs has been enriched by finerenone. This molecule has favourable pharmacokinetic characteristics compared with previous medications of the same class and tested in Phase 3, randomized, placebo-controlled trials (FIDELIO-DKD and FIGARO-DKD) which has been shown to significantly reduce the risk of cardiovascular and renal disease in diabetic patients compared with placebo."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Infarction • Nephrology • Renal Disease • Transplantation • Type 2 Diabetes Mellitus

Focus on finerenone: the FINEARTS-HF study. (PubMed, Eur Heart J Suppl) - "Moreover, the FINEARTS-HF study demonstrated consistent efficacy across the entire left ventricular ejection fraction (LVEF) spectrum, regardless of sodium-glucose cotransporter 2 inhibitors use, sex, or age, with an early onset of benefit and a favourable safety and tolerability profile. Finerenone is currently indicated in class I in diabetic patients with chronic kidney disease to reduce the risk of HF; in light of the FINEARTS-HF results, it could become a new pillar of therapy for patients with HFpEF and HFmrEF."

Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease

Trade-off of risk and benefit of finerenone across the spectrum of kidney function in patients with heart failure with mildly reduced and preserved ejection fraction in the FINEARTS-HF trial (HEART FAILURE 2025) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

Effects of finerenone on readmissions for heart failure: a prespecified secondary analysis of the FINEARTS-HF trial (HEART FAILURE 2025) - No abstract available

Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

Finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomized placebo-controlled mechanistic trial (FIVE-STAR) (HEART FAILURE 2025) - No abstract available

Biomarker • Clinical • Late-breaking abstract • Cardiovascular • Congestive Heart Failure • Heart Failure

Finerenone (HEART FAILURE 2025) - "Sponsored by Joint session with the Canadian Heart Failure Society"

Cardiovascular • Congestive Heart Failure • Heart Failure

The efficacy and tolerability of finerenone related to the use and dosage of diuretics at baseline in FINEARTS-HF (HEART FAILURE 2025) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure

The effect of finerenone on the total burden of heart failure events in the FINEARTS-HF trial analysed using the weighted composite endpoint method (HEART FAILURE 2025) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Effect of finerenone on morbidity and mortality in chronic kidney disease and type 2 diabetes: FINE-HEART analysis of 3 randomized clinical trials (HEART FAILURE 2025) - No abstract available

Clinical • Cardiovascular

The applicability of finerenone therapy across the broad spectrum of cardiovascular-kidney-metabolic syndrome: shaken not stirred (HEART FAILURE 2025) - No abstract available

Cardiovascular • Congestive Heart Failure • Heart Failure

Epidemiological profile of heart failure patients with diabetic kidney disease initiating finerenone: insights from real-world data (FINARM STUDY) (HEART FAILURE 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure

Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial (HEART FAILURE 2025) - No abstract available

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure